drugset / Trial / NCT05803135
Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis
Phase 4
Unknown
138 enrolled
Nanfang Hospital, Southern Medical University
Jiangsu Simcere Pharmaceutical Co., Ltd. · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to assess the efficacy and safety of Iguratimod combined with Tofacitinib in the treatment of csDMARD-IR patients with active moderate-to-severe rheumatoid arthritis
Timeline
- Start
- 2023-03-31
- Primary completion
- 2025-01-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Iguratimod | Small molecule | 25 mg | Oral |
| Comparator | Tofacitinib | Small molecule | 5 mg | Oral |